Targeting DNA methylation in AML has gained significant attention, given the fact that it represents a potential therapeutic strategy to reverse the epigenetic dysregulations that contribute to disease progression, drug resistance, and inferior prognostic impact in the presence of FLT3-ITD mutations. Here, FLT3 is linked to acute myeloid leukemia.